Challenges with advanced therapy medicinal products and how to meet them
- 1 March 2010
- journal article
- opinion
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 9 (3), 195-201
- https://doi.org/10.1038/nrd3052
Abstract
Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products, are at the cutting edge of innovation and offer a major hope for various diseases for which there are limited or no therapeutic options. They have therefore been subject to considerable interest and debate. Following the European regulation on ATMPs, a consolidated regulatory framework for these innovative medicines has recently been established. Central to this framework is the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA), comprising a multidisciplinary scientific expert committee, representing all EU member states and European Free Trade Association countries, as well as patient and medical associations. In this article, the CAT discusses some of the typical issues raised by developers of ATMPs, and highlights the opportunities for such companies and research groups to approach the EMA and the CAT as a regulatory advisor during development.Keywords
This publication has 18 references indexed in Scilit:
- Articular cartilage tissue engineeringThe Journal of Bone and Joint Surgery. British volume, 2009
- Preventing and exploiting the oncogenic potential of integrating gene vectorsJCI Insight, 2009
- An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cellsProceedings of the National Academy of Sciences, 2009
- Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia PatientPLoS Medicine, 2009
- Gene Therapy for Immunodeficiency Due to Adenosine Deaminase DeficiencyNew England Journal of Medicine, 2009
- Gene Therapy Fulfilling Its PromiseNew England Journal of Medicine, 2009
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Inducible Packaging Cells for Large-scale Production of Lentiviral Vectors in Serum-free Suspension CultureMolecular Therapy, 2008
- A Clinical Development Paradigm for Cancer Vaccines and Related BiologicsJournal of Immunotherapy, 2007
- The moving fingerNature, 2005